Renalytix (LSE:RENX) Change In Receivables : £0.15 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Renalytix Change In Receivables?

Renalytix's change in receivables for the quarter that ended in Mar. 2024 was £0.64 Mil. It means Renalytix's Accounts Receivable declined by £0.64 Mil from Dec. 2023 to Mar. 2024 .

Renalytix's change in receivables for the fiscal year that ended in Jun. 2023 was £0.10 Mil. It means Renalytix's Accounts Receivable declined by £0.10 Mil from Jun. 2022 to Jun. 2023 .

Renalytix's Accounts Receivable for the quarter that ended in Mar. 2024 was £0.44 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Renalytix's Days Sales Outstanding for the three months ended in Mar. 2024 was 94.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Renalytix's liquidation value for the three months ended in Mar. 2024 was £-11.62 Mil.

Renalytix Change In Receivables Historical Data

The historical data trend for Renalytix's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Change In Receivables Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

-0.01

-0.41

-0.25

0.10

Renalytix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.11	-0.02	-0.19	-0.28	0.64

Renalytix Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £0.15 Mil.

Renalytix (LSE:RENX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Renalytix's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.436	/	0.421	*	91
=	94.50

2. In Ben Graham's calculation of liquidation value, Renalytix's accounts receivable are only considered to be worth 75% of book value:

Renalytix's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.702	-	15.646	+	0.75 * 0.436	+	0.5 * 0
=	-11.62

Renalytix Change In Receivables Related Terms

Thank you for viewing the detailed overview of Renalytix's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (LSE:RENX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

RNLX:USA RTNXF:USA 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex • 12-14-2012

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe • 08-29-2013

Omnicom Health Group acquires Elsevier's Pharma Communications business in Japan, rebrands as EMC K.K.

By PRNewswire PRNewswire • 03-27-2018

Investing in Information

By Vanina Egea Vanina Egea • 03-06-2014